161 related articles for article (PubMed ID: 38231444)
1. Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53.
Kinney BLC; Gunti S; Kansal V; Parrish CJ; Saba NF; Teng Y; Henry MK; Su FY; Kwong GA; Schmitt NC
Cancer Immunol Immunother; 2024 Jan; 73(1):10. PubMed ID: 38231444
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.
Leibowitz MS; Andrade Filho PA; Ferrone S; Ferris RL
Cancer Immunol Immunother; 2011 Apr; 60(4):525-35. PubMed ID: 21207025
[TBL] [Abstract][Full Text] [Related]
3. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.
Leibowitz MS; Srivastava RM; Andrade Filho PA; Egloff AM; Wang L; Seethala RR; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Feb; 19(4):798-808. PubMed ID: 23363816
[TBL] [Abstract][Full Text] [Related]
4. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
Schmitt NC; Trivedi S; Ferris RL
Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
[TBL] [Abstract][Full Text] [Related]
5. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway.
Luo X; Qiu Y; Fitzsimonds ZR; Wang Q; Chen Q; Lei YL
Oncogene; 2024 Feb; 43(6):388-394. PubMed ID: 38177410
[TBL] [Abstract][Full Text] [Related]
6. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
7. SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
Tanagala KKK; Morin-Baxter J; Carvajal R; Cheema M; Dubey S; Nakagawa H; Yoon A; Cheng YL; Taylor A; Nickerson J; Mintz A; Momen-Heravi F
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600652
[TBL] [Abstract][Full Text] [Related]
8. Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma.
Knitz MW; Darragh LB; Bickett TE; Bhatia S; Bukkapatnam S; Gadwa J; Piper M; Corbo S; Nguyen D; Van Court B; Oweida A; Karam SD
Cancer Immunol Immunother; 2022 May; 71(5):1049-1061. PubMed ID: 34559306
[TBL] [Abstract][Full Text] [Related]
9. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.
Srivastava RM; Trivedi S; Concha-Benavente F; Hyun-Bae J; Wang L; Seethala RR; Branstetter BF; Ferrone S; Ferris RL
Cancer Immunol Res; 2015 Aug; 3(8):936-45. PubMed ID: 25972070
[TBL] [Abstract][Full Text] [Related]
10. STAT1 is regulated by TRIM24 and promotes immunosuppression in head and neck squamous carcinoma cells, but enhances T cell antitumour immunity in the tumour microenvironment.
Anderson K; Ryan N; Nedungadi D; Lamenza F; Swingler M; Siddiqui A; Satoskar A; Upadhaya P; Pietrzak M; Oghumu S
Br J Cancer; 2022 Sep; 127(4):624-636. PubMed ID: 35595823
[TBL] [Abstract][Full Text] [Related]
11. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
12. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
13. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL.
López-Albaitero A; Nayak JV; Ogino T; Machandia A; Gooding W; DeLeo AB; Ferrone S; Ferris RL
J Immunol; 2006 Mar; 176(6):3402-9. PubMed ID: 16517708
[TBL] [Abstract][Full Text] [Related]
14. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
15. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
[TBL] [Abstract][Full Text] [Related]
16. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
[TBL] [Abstract][Full Text] [Related]
17. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.
Ryan N; Anderson K; Volpedo G; Hamza O; Varikuti S; Satoskar AR; Oghumu S
Int J Cancer; 2020 Mar; 146(6):1717-1729. PubMed ID: 31709529
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.
Ma H; Yang W; Zhang L; Liu S; Zhao M; Zhou G; Wang L; Jin S; Zhang Z; Hu J
Br J Cancer; 2019 Feb; 120(3):317-330. PubMed ID: 30555157
[TBL] [Abstract][Full Text] [Related]
19. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
20.
García-Carracedo D; Cai Y; Qiu W; Saeki K; Friedman RA; Lee A; Li Y; Goldberg EM; Stratikopoulos EE; Parsons R; Lu C; Efstratiadis A; Philipone EM; Yoon AJ; Su GH
Mol Cancer Res; 2020 Jun; 18(6):822-834. PubMed ID: 32152233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
